HIV Medicine

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients
pp. 527-535(9)
Authors: Hill, A; Sawyer, W

Boosted protease inhibitors as a therapeutic option in the treatment of HIV-infected children
pp. 536-547(12)
Author: Ramos, JT

Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma
pp. 548-554(7)
Authors: Lorello, G; la Porte, C; Pilon, R; Zhang, G; Karnauchow, T; MacPherson, P

The individual and combined influence of HIV and hepatitis C virus on dyslipidaemia in a high-risk Hispanic population
pp. 555-563(9)
Authors: Forrester, JE; McGovern, BH; Rhee, MS; Sterling, RK

Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS
pp. 564-572(9)
Authors: Gutierrez, EB; Gomes, V; Picone, CM; Suga, H; Atomiya, AN

The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients
pp. 573-579(7)
Authors: Suarez-Lozano, I; Viciana, P; Lacalle, J-R; Teira, R; Lozano, F; Lopez-Aldeguer, J; Pedrol, E; Domingo, P; Cosin, J; Roca, B; Geijo, P; Fuente, B; Vergara, A; Ribera, E; Galindo, M-J; Zapata, A; Sanchez, T; Vidal, F; Munoz-Sanz, A; Munoz-Sanchez, J; Garrido, M

Impact of hyperglycaemia and cholesterol levels on the outcome of hepatitis C virus (HCV) treatment in HIV/HCV-coinfected patients
pp. 580-585(6)
Authors: Cesari, M; Caramma, I; Antinori, S; Adorni, F; Galli, M; Milazzo, L

Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach
pp. 586-589(4)
Authors: Dailly, E; Raffi, F; Perré, P; Martin, J; Deslandes, G; Jolliet, P